Protagonist Therapeutics to Present on Rusfertide at ASCO 2025

Protagonist Therapeutics, headquartered in Newark, California, announced that its abstract on the VERIFY Phase 3 study has been chosen for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3, 2025. Dr. Andrew T. Kuykendall from Moffitt Cancer Center will present the study results on June 1, 2025, during the Plenary Session at McCormick Place, Hall B1.

The study focuses on Rusfertide, a treatment for polycythemia vera (PV), assessed in a double-blind, placebo-controlled Phase 3 trial. Rusfertide, a hepcidin mimetic, is being co-developed with Takeda Pharmaceuticals. Protagonist Therapeutics aims to file a New Drug Application later this year.